

# Intellectual Property Prospector

IP Assets Held by Firms In Transition

June 18, 2007  
Volume 2, Number 25  
Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
2-Track Global, Inc.	<a href="#">07.0909</a>	Loss/Deficit
Actis Global Ventures, Inc.	<a href="#">07.0910</a>	Audit Concerns
Arbios Systems, Inc.	<a href="#">07.0911</a>	Audit Concerns
Berry Plastics Holding Corporation	<a href="#">07.0912</a>	Low Rating
Biophan Technologies, Inc.	<a href="#">07.0913</a>	Audit Concerns
Calbatech, Inc.	<a href="#">07.0914</a>	Audit Concerns
Callisto Pharmaceuticals, Inc.	<a href="#">07.0915</a>	Audit Concerns
Canadian Rockport Homes International, Inc.	<a href="#">07.0916</a>	Audit Concerns
CepTor Corporation	<a href="#">07.0917</a>	Audit Concerns
Dealer Advance, Inc.	<a href="#">07.0918</a>	Loss/Deficit
Duska Therapeutics, Inc.	<a href="#">07.0919</a>	Audit Concerns
EESTech, Inc.	<a href="#">07.0920</a>	Loss/Deficit
EnerTeck Corporation	<a href="#">07.0921</a>	Loss/Deficit
GS CleanTech Corporation	<a href="#">07.0922</a>	Audit Concerns
Hydrogen Engine Center, Inc.	<a href="#">07.0923</a>	Audit Concerns
instaCare Corporation	<a href="#">07.0924</a>	Loss/Deficit
Lamperd Less Lethal, Inc.	<a href="#">07.0925</a>	Loss/Deficit
Leisure Direct, Inc.	<a href="#">07.0926</a>	Loss/Deficit
Life USA, Inc.	<a href="#">07.0927</a>	Audit Concerns
Lucy's Café, Inc.	<a href="#">07.0928</a>	Loss/Deficit
MetaMorphix, Inc.	<a href="#">07.0929</a>	Loss/Deficit
Nano-Jet Corporation	<a href="#">07.0930</a>	Audit Concerns
New Century Financial Corporation	<a href="#">07.0931</a>	IP Asset Sale
NS8 Corporation	<a href="#">07.0932</a>	Audit Concerns
Optigenex, Inc.	<a href="#">07.0933</a>	Audit Concerns
Protocall Technologies, Inc.	<a href="#">07.0934</a>	Loss/Deficit
Rockelle Corporation	<a href="#">07.0935</a>	Audit Concerns
Ronco Corporation	<a href="#">07.0936</a>	Bankruptcy

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Seawright Holdings, Inc.	<a href="#">07.0937</a>	Loss/Deficit
SenoRx, Inc.	<a href="#">07.0938</a>	Loss/Deficit
SurgiLight, Inc.	<a href="#">07.0939</a>	Audit Concerns
Tweeter Home Entertainment Group, Inc.	<a href="#">07.0940</a>	Bankruptcy
Valence Technology, Inc.	<a href="#">07.0941</a>	Audit Concerns
Vaso Active Pharmaceuticals, Inc.	<a href="#">07.0942</a>	Audit Concerns
Vistula Communications, Inc.	<a href="#">07.0943</a>	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

**Intellectual Property Prospector** identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

### **Prospector Profile Selection Criteria:**

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

**DISCLAIMER:** The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

**ACCURACY & COVERAGE:** The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

**SUBSCRIPTIONS:** Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

**Intellectual Property Prospector** is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector  
Profile  
07.0909**

**2-Track Global, Inc.**

35 Argo House, Kilburn Park Road  
London, United Kingdom NW6 5LF  
011-44-20-7644-0472

NAICS		334220
Description		Transceivers Mfg.
Employees		3
Revenue	(mil)	\$0.41
Income	(mil)	(\$1.45)
Assets	(mil)	\$0.13
Liability	(mil)	\$1.94
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** 2-Track Global, Inc. reported a net loss for the quarter ending March 31, 2007 of \$342,138 on revenues of \$20,868, higher than the net loss reported during the same period last year of \$215,159 on revenues of \$101,207. As a result of its recurring losses, the Company has an accumulated deficit of \$3,270,609 and stockholder's deficit of \$2,144,617 as of March 31, 2007. The Company also has strained liquidity with \$251,305 in total current assets and \$2,428,630 in total current liabilities.

**Intellectual Property:** The Company owns all the intellectual property for its PRISMS™ technology for container monitoring. This includes all the requirements, firmware and software design and planning, and other copyright encompassed in the technical specification for the communications architecture and its specific deployment for the business applications, subject to a PCT Application through the Korean Patent Office in November 2004. The Company also owns the intellectual property rights to two middleware/software applications used for the reporting and presentation of data captured from remote assets such as vehicles, vessels or containers - using PRISMS™ or other GSM-equipped devices, although in most instances third-party GIS licenses are embedded in the final software product. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company develops and commercializes highly profitable niche telematics solutions in new high-growth markets such as freight containers and commercial vehicles.

**Officers:** Woosun Jung (Chair, Pres. & CEO); Frank Snorheim (Dir.)

**Auditor:** Michael T. Studer CPA P.C.

**Securities:** Common Stock-Symbol TOTG.OB; OTC BB;  
35,577,513 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0910**

**Actis Global Ventures, Inc.**

1905 Aston Avenue, Suite 101  
Carlsbad, CA 92008  
(760) 448-2498

NAICS	454390
Description	Direct Selling
Employees	21
Revenue (mil)	\$10.54
Income (mil)	(\$5.55)
Assets (mil)	\$1.59
Liability (mil)	\$10.57
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Squar, Milner, Peterson, Miranda & Williamson, LLP states that there is substantial doubt about Actis Global Ventures, Inc.'s ability to continue as a going concern after auditing its financial statements. The Company has incurred losses since inception totaling \$14,857,179 through December 31, 2006, and as of December 31, 2006 has a working capital deficit of \$9,465,098.

**Intellectual Property:** The Company's core product concept is based on products developed using Energy Resonance Technology (ERT™) and the patented noise field Molecular Resonance Effect Technology (MRET™). The Company's trademarks include Channoine®, BIOPRO CELL CHIP™, VITATONIC™, QX-3™, BIOPRODUCE™, BIOPRO Home Harmonizer™, and LEANCHOICES™. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company markets a variety of leading edge wellness products in the areas of Bioenergetics, Nutrition and Beauty through the Direct Sales and Direct Response Television channels.

**Officers:** Ray W. Grimm, Jr. (CEO, Acting CFO & Dir.); Alfred Hanser (Pres., Sec. & Dir.); Joseph V. Caracciolo (Dir.)

**Auditor:** Squar, Milner, Peterson, Miranda & Williamson, LLP

**Securities:** Common Stock-Symbol AGLV.OB; OTC BB;  
309,285,122 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0911**

**Arbios Systems, Inc.**

1050 Winter Street, Suite 1000  
Waltham, MA 02451  
(781) 839-7293

NAICS		339113
Description		Implants Mfg.
Employees		6
Revenue	(mil)	\$0.00
Income	(mil)	(\$4.46)
Assets	(mil)	\$2.49
Liability	(mil)	\$1.21
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Stonefield Josephson, Inc. notes that Arbios Systems, Inc. has suffered recurring losses from operations and has an accumulated deficit, and has been dependent on outside equity to finance operations, all of which raise substantial doubt about its ability to continue as a going concern

**Intellectual Property:** The Company's intellectual property rights relating to the SEPET™ Liver Assist Device consist of a U.S. patent application plus pending foreign counterpart applications, a family of in-licensed U.S. patents plus foreign counterparts and pending patent applications, and certain related trade secrets. The Company originally obtained exclusive, worldwide rights from Cedars-Sinai Medical Center and Spectrum Laboratories to seven issued U.S. patents protecting the bioartificial liver technology and accompanying cell procurement/cryopreservation technologies. In April 2004, it acquired from Circe Biomedical a portfolio of intellectual properties, including certain U.S. and foreign patents applicable to the HepatAssist™ bioartificial liver that Circe Biomedical was developing, including various patents related to the harvesting and handling of cells to be used in the bioartificial liver. The Company has filed for trademark protection for its product names, SEPET™ and HepatAssist™. [SEC Filing 10-KSB 04-17-07]

**Description:** Arbios operates as a medical device and cell-therapy company that develops products for the treatment of liver failure in the United States.

**Officers:** Walter C. Ogier (Pres., CEO & Dir.); John M. Vierling, M.D. (Chair); Scott L. Hayashi (VP, CFO & Sec.); David J. Zeffren (VP); Shawn P. Cain (VP); Jack E. Stover (Dir.); Thomas C. Seoh (Dir.); Thomas M. Tully (Dir.); Dennis Kogod (Dir.);

**Auditor:** Stonefield Josephson, Inc.

**Securities:** Common Stock-Symbol ARBOS.OB; OTC BB;  
17,460,181 common shares outstanding as of March 29, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0912**

**Berry Plastics Holding Corporation**

101 Oakley Street  
Evansville, IN 47710  
(812) 424-2904

NAICS		326199
Description		Plastics Mfg.
Employees		6,600
Revenue	(mil)	\$383.29
Income	(mil)	(\$18.07)
Assets	(mil)	\$2,568.66
Liability	(mil)	\$2,274.47
(for the year ended 12/30/2006)		

**Category:** Low Rating

**Event:** Moody's Investors Service downgraded Berry Plastics Holding Corp.'s \$265 million senior subordinated notes due 2016 to Caa1, LGD5, 82% from Caa2, LGD6, 90%. Moody's also affirmed its Caa2, LGD6, 93% rating on the Company's \$500 million senior unsecured term loan due 2014. The rating outlook is stable.

**Intellectual Property:** The Company relies on a combination of patents, trade secrets, unpatented know-how, trademarks, copyrights and other intellectual property rights, nondisclosure agreements and other protective measures to protect proprietary rights. The Company employs various methods, including confidentiality and non-disclosure agreements with third parties, employees and consultants, to protect trade secrets and know-how. The Company has licensed, and may license in the future, patents, trademarks, trade secrets, and similar proprietary rights to and from third parties. [SEC Filing 10-K 03-12-07]

**Description:** The Company manufactures injection-molded plastic products such as containers, closures, and consumer products such as plastic drink cups and housewares.

**Officers:** Ira G. Boots (Pres., CEO & Dir.); R. Brent Beeler (EVP & COO); James M. Kratochvil (EVP, CFO, Treas. & Sec.); Anthony M. Civale (Dir.); Patrick J. Dalton (Dir.); Donald C. Graham (Dir.); Steven C. Graham (Dir.); Joshua J. Harris (Dir.); Robert V. Seminara (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** 100 common shares outstanding as of March 1, 2007.  
8-7/8% second priority fixed rate notes due September 15, 2014; LIBOR plus 3.875% second priority senior secured floating rate notes due September 15, 2010; 11% senior subordinated notes due 2016; 10-3/4% senior subordinated notes due 2012.

**Notes:** There is no established public trading market for the Company's common stocks.

[Return to top](#)

**Prospector  
Profile  
07.0913**

**Biophan Technologies, Inc.**

15 Schoen Place  
Pittsford, NY 14534  
(585) 267-4800

NAICS	541710
Description	Biotechnology
Employees	22
Revenue (mil)	\$0.99
Income (mil)	(\$17.72)
Assets (mil)	\$28.90
Liability (mil)	\$32.11
(for the year ended 2/28/2007)	

**Category:** Audit Concerns

**Event:** Goldstein Golub Kessler LLP states that there is potential doubt about the ability of Biophan Technologies, Inc. to continue as a going concern after auditing its financial statements. The Company has incurred recurring losses from operations, and as of February 28, 2007, the Company's current liabilities exceeded its current assets by \$4,787,059 and has a stockholders' deficiency of \$3,210,045.

**Intellectual Property:** The Company's total U.S. portfolio of patents owned as well as exclusively licensed includes 61 issued patents and over 60 applications at various stages of examination at the U.S. Patent and Trademark Office. The key technology areas that the patents cover include Photonics, Discrete Components and Circuits, Anti-Antenna Geometries, Nanomagnetic Thin-Film Coatings, Resonant Circuit Structures, Biothermal Power Source, Pulse-width Cardiac Pacing, and Lead and Electrical Components. The name "Biophan" is a registered trademark of the Company; and it has filed for registration of the trademarks Nanolution, Nanolute and Nanoview. [SEC Filing 10-K 05-07-07]

**Description:** The Company engages in the development and commercialization of technologies for use with medical procedures and biomedical devices.

**Officers:** Guenter H. Jaensch (Chair); Michael L. Weiner (Pres., CEO & Dir.); John F. Lanzafame (VP & COO); Darryl L. Canfield (VP, Treas., Sec. & CFO); Stuart G. MacDonald (VP); Jeffery L. Helfer (VP); Theodore A. Greenberg (Dir.); Bonita L. Labosky (Dir.); Stan Yakatan (Dir.)

**Auditor:** Goldstein Golub Kessler LLP

**Securities:** Common Stock-Symbol BIPH.OB; OTC BB; 83,431,699 common shares outstanding as of April 25, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0914**

**Calbotech, Inc.**

15375 Barranca Parkway, Suite I-101  
Irvine, CA 92618  
(949) 450-9910

NAICS	541710
Description	Biotechnology
Employees	16
Revenue (mil)	\$1.25
Income (mil)	\$0.01
Assets (mil)	\$0.52
Liability (mil)	\$5.27
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** De Joya Griffith & Company, LLC notes that Calbotech, Inc. has suffered recurring losses from operations, negative working capital, and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern.

**Intellectual Property:** CalbaTech has filed two patent application for intellectual property relating to a device for the efficient and effective delivery of stem cells to diseased or dead areas of the heart and a method of collecting and storing two different types of stem cells in micro quantities for autologous use. The first of these patent applications entitled "Device and methods for processing sample and detecting analytes at low concentration" is a US Patent Application Serial No. 11/034,227 filed 01/12/05 by James Zoval, Ph.D. This application describes a novel concept for the isolation and purification of DNA and other biological molecules. The second patent application was entitled "Cardiac Stem Cell Delivery Apparatus", by inventor Jason Van Tassel, M.D. This patent describes a modification of endoscope technology which will facilitate the targeted delivery of adult stem cells to specific tissues. CalbaTech has filed a third US Patent Application, Serial No. 11/591,434, entitled "methods for harvesting and storing autologous stem cells including blood derived hematopoietic stem cell and adipose derived mesenchymal stem cells", filed October 31st 2006. This describes specific methods and processes associated with adult stem cell storage which will be incorporated into LifeStem's business model. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company focuses on acquiring, incubating and developing early-stage science-related companies.

**Officers:** James DeOlden, Esq. (CEO & Dir.); Edward H. Deese (Pres., COO & Dir.); John Gordon, Ph.D. (Chief Technology Officer & Dir.)

**Auditor:** De Joya Griffith & Company, LLC

**Securities:** Common Stock-Symbol CLBE.OB; OTC BB;  
121,270,079 common shares outstanding as of March 5, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0915**

**Callisto Pharmaceuticals, Inc.**

420 Lexington Avenue, Suite 1609  
New York, NY 10170  
(212) 297-0010

NAICS	541710
Description	Biotechnology
Employees	9
Revenue (mil)	\$0.00
Income (mil)	(\$12.92)
Assets (mil)	\$4.05
Liability (mil)	\$3.20
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** BDO Seidman, LLP raised doubts on the ability of Callisto Pharmaceuticals, Inc. to continue as a going concern due to its recurring losses from operations and net capital deficiency.

**Intellectual Property:** As of December 31, 2006, the Company is the assignee or exclusive licensee of 7 pending patent applications and 15 issued patents in the United States, and currently has approximately 150 issued or pending foreign patent applications. The Company seeks patent protection of inventions originating from ongoing research and development activities that are commercially important to its business. The composition-of-matter patents for L-Annamycin and Atiprimod expire in 2017 and 2016, respectively. The formulation patents for L-Annamycin and Atiprimod dimaleate salt both expire in 2016. The Company has obtained licenses from various parties that give them the rights to technologies that are necessary or desirable for research and development. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company focuses on the development of drugs to treat neuroendocrine cancer, acute leukemia, and multiple myeloma.

**Officers:** Gabriele M. Cerrone (Chair); Gary S. Jacob (CEO, Chief Scientific Officer & Dir.); Bernard F. Denoyer (VP & Sec.); Daniel S. D'Agostino (Chief Business Officer); John P. Brancaccio (Dir.); Christoph Bruening (Dir.); Riccardo Dalla-Favera (Dir.); Stephen K. Carter (Dir.); Randall Johnson (Dir.)

**Auditor:** BDO Seidman, LLP

**Securities:** Common Stock-Symbol KAL; AMEX;  
39,194,996 common shares outstanding as of April 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0916**

**Canadian Rockport Homes International, Inc.**

2317 Wall Street  
Vancouver, British Columbia, Canada V5L 1B8  
(604) 669-1081

NAICS	236117
Description	Modular Homes
Employees	99
Revenue (mil)	\$0.00
Income (mil)	(\$2.48)
Assets (mil)	\$5.26
Liability (mil)	\$2.20
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Farber Hass Hurley & McEwen LLP expressed substantial doubt about Canadian Rockport Homes International, Inc.'s ability to continue as a going concern after auditing its financial statements. The auditor points out that the Company has incurred significant operating losses, has not generated any revenues, is currently in default on a significant portion of its debt and has a deficit accumulated during the development stage. The Company has also not yet demonstrated the ability to conduct operations profitably.

**Intellectual Property:** The Company is relying heavily upon its use of the TWiC technology to carry out its plan of operations. Thus, the Company has purchased TWiC technology which is patented and is taking reasonable steps to protect the technology from being copied by any third party. The TWiC technology bears the United States Patent No. 5,997,792 and was filed on December 7, 1999. The Company also has a patent on its technology in Chile. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company plans to manufacture and construct low-cost concrete modular housing in developing nations and third-world countries.

**Officers:** Dr. William R. Malone (Chair, Pres. & CEO); Grissel Rojas (CFO); Chris Kinch (Dir.); Donel P. Belsby (Dir.)

**Auditor:** Farber Hass Hurley & McEwen LLP

**Securities:** 17,659,636 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0917**

**CepTor Corporation**

462 Seventh Avenue, Suite 1200  
New York, NY 10018  
(212) 629-0804

NAICS		541710
Description		Biotechnology
Employees		1
Revenue	(mil)	\$0.00
Income	(mil)	(\$8.16)
Assets	(mil)	\$1.25
Liability	(mil)	\$14.87
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** WithumSmith+Brown, P.C. expressed substantial doubt about the ability of CepTor Corporation to continue as a going concern after auditing its financial statements. The Company has sustained recurring operating losses and has an accumulated deficit of \$915,846 as of December 31, 2006.

**Intellectual Property:** The Company's intellectual property portfolio includes 4 patents registered with the U.S. Patent and Trademark Office and 3 PCT international patent applications. At present, the Company's patent protection for Myodur™ extends solely to the United States. Provisional patents for Neurodur™ are scheduled to expire shortly, and the Company is in the process of securing final patent protection for the US, the European Union and Japan. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company is engaged in the research and development of therapeutic products for neuromuscular, neurodegenerative, and other diseases with a focus on orphan diseases.

**Officers:** Howard Becker (CEO & Dir.); Tony Coelho (Dir.)

**Auditor:** WithumSmith+Brown, P.C.

**Securities:** Common Stock-Symbol CEPO.OB; OTC BB;  
15,550,069 common shares outstanding as of April 11, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0918**

**Dealer Advance, Inc.**

16801 Addison Road, Suite 310  
Addison, TX 75001  
(214) 866-0606

NAICS		511210
Description		Software Publishers
Employees		7
Revenue	(mil)	\$0.48
Income	(mil)	(\$4.44)
Assets	(mil)	\$0.25
Liability	(mil)	\$12.55
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Dealer Advance, Inc. reported a net loss of \$1,110,80 on sales of \$59,254 for the first quarter ending March 31, 2007, slightly higher than the net loss reported during the same period last year of \$1,031,190 on sales of \$143,729. As a result of its recurring losses, the Company has an accumulated depreciation of \$24,273,140 and stockholder's deficit of \$13,412,828 as of March 31, 2007. It also has strained liquidity with \$162,531 in total current assets and \$9,704,677 in total current liabilities.

**Intellectual Property:** The Company owns a trademark for DealerAdvance™ and has one patent application pending covering the system for management of information flow in automotive dealerships using handheld technology. The patent application is currently being reviewed by the United States Patent and Trademark Office. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company is an enterprise software solutions provider.

**Officers:** Steven E. Humphries (Pres., CEO & Dir.)

**Auditor:** Paritz & Company, P.A.

**Securities:** Common Stock-Symbol DLAV.OB; OTC BB;  
47,751,393 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0919**

**Duska Therapeutics, Inc.**

Two Bala Plaza, Suite 300  
Bala Cynwyd, PA 19004  
(610) 660-6690

NAICS	541710
Description	Biotechnology
Employees	1
Revenue (mil)	\$0.00
Income (mil)	(\$2.00)
Assets (mil)	\$0.36
Liability (mil)	\$1.25
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Stonefield Josephson, Inc. expressed substantial doubt on Duska Therapeutics, Inc.'s ability to continue as a going concern after auditing its financial statements. The auditor states that the going concern opinion was a result of recurring negative cash flows from operations and accumulated deficit of approximately \$8,425,000 as of December 31, 2006. Its ability to continue as a going concern is subject to the ability to obtain significant additional capital to fund operations. If it fails to raise sufficient capital, the auditor believes that that the Company may have to liquidate its business.

**Intellectual Property:** The Company's technology and current and proposed product candidates under development are currently covered by seven U.S. patents and corresponding pending patent applications in Europe, Canada, Australia and Japan. In addition to patents, it also licenses certain intellectual property. The Company's trademarks include ATPace™, ATPotent™, Aspirex™, Vagonixen™ and Ocuprene™. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company focusing on the development of diagnostic and therapeutic products based on adenosine 5'-triphosphate (ATP), and P2 receptors.

**Officers:** Amir Pelleg, Ph.D. (Chair, Pres., COO & Chief Scientific Officer); Wayne Lorgus (CFO); David Benditt, M.D. (Dir.); Jane F. Kinsel, Ph.D. (Dir.); Donald Alan McAfee, Ph.D. (Dir.);

**Auditor:** Stonefield Josephson, Inc.

**Securities:** Common Stock-Symbol DSKA.OB; OTC BB;  
2,492,584 common shares outstanding as of March 27, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0920**

**EESTech, Inc.**

23011 Moulton Parkway A-10  
Laguna Hills, CA 92653  
(949) 380-4033

NAICS		333319
Description		Water Purification Equipment
Employees		1
Revenue	(mil)	\$0.00
Income	(mil)	(\$1.87)
Assets	(mil)	\$0.11
Liability	(mil)	\$0.39
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** EESTech, Inc. reported a net loss of \$261,896 for the quarter ending March 31, 2007, compared to a net loss of \$307,005 during the same period a year ago. As a result of its recurring losses, the Company has an accumulated deficit of \$12,459,42 and stockholder's deficit of \$445,767 as of March 31, 2007. The Company also has strained liquidity with \$173,462 in total current assets available to pay \$703,394 in total current liabilities.

**Intellectual Property:** The Company holds an exclusive license in the HCGT technology from ComEnergy Pty. Ltd. for the commercialization of the technology in North America. In addition, the Company holds a specific license to supply and operate an HCGT plant for the Fuxin Coal Group in the People's Republic of China. The patents reflected in the license are registered by one of the Australian Government's Scientific and Industrial Research entities. There are four basic families of patents/patent applications with respect to the JetWater System: Water Distillation System (all based on Australian Provisional Patent Application PQ5402/Filing date 02.02.00); Water Distillation System (a different design to PQ5402 based on Australian Provisional Patent Application 2004905255/Filing date 14.09.04); A Distributor for a Flowable Medium (based on Aust Provisional Patent Application 2005904279/Filing date 09.08.05); and a Pressure Relief Assembly. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides solutions utilizing economically and environmentally sustainable technologies.

**Officers:** Murray Bailey (CEO, CFO & Dir.); Gaylord Beeson (Dir.)

**Auditor:** Vasquez & Co. LLP

**Securities:** Common Stock-Symbol EESH.OB; OTC BB;  
18,277,393 common shares outstanding as of May 10, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0921**

**EnerTeck Corporation**

10701 Corporate Drive, Suite 150  
Stafford, TX 77477  
(281) 240-1787

NAICS		325998
Description		Fuel Additives Mfg.
Employees		5
Revenue	(mil)	\$0.64
Income	(mil)	(\$0.64)
Assets	(mil)	\$4.07
Liability	(mil)	\$2.10
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** EnerTeck Corp. reported a net loss of \$220,224 on sales of \$37,180 for the first quarter ending March 31, 2007, a substantial increase over the net loss reported during the same period last year of \$146,286 on sales of \$271,700. As of March 31, 2007, the Company has \$17,092,568 in accumulated deficit.

**Intellectual Property:** The Company owns the EnerBurn trademark and the EnerBurn formulas and technology. On July 13, 2006, the Company completed the acquisition of the EnerBurn formulas, technology and associated assets pursuant to an Asset Purchase Agreement with Ruby Cat Technology LLC. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the manufacture, sale, and marketing of fuel borne catalytic engine treatment products for diesel engines.

**Officers:** Dwaine Reese (Chair & CEO); Stan Crow (Pres.); Richard B. Dicks (CFO); Gary B. Aman (Dir.); Jack D. Cowles (Dir.); Thomas F. Donino (Dir.)

**Auditor:** Philip Vogel & Co. PC

**Securities:** Common Stock-Symbol ETCK.OB; OTC BB;  
16,761,359 common shares outstanding as of April 30, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0922**

**GS CleanTech Corporation**

One Penn Plaza, Suite 1612  
New York, NY 10119  
(212) 994-5374

NAICS		541330
Description		Engineering Services
Employees		58
Revenue	(mil)	\$14.44
Income	(mil)	(\$9.87)
Assets	(mil)	\$14.38
Liability	(mil)	\$23.17
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Rosenberg Rich Baker Berman & Company raised substantial doubt about the ability of GS CleanTech Corporation to continue as a going concern after auditing its financial statements. The Company has suffered recurring losses from operations and has working capital deficiency of \$13,596,000 and an accumulated deficit of \$60,564,000 as of December 31, 2006.

**Intellectual Property:** The Company holds a number of trademarks including: GS CleanTech, GS CleanTech Corporation Environmental, the "GS CleanTech Corporation Logo" and the tagline "A Clear Vision for a Better Environment". [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides applied engineering and technology transfer services based on clean technologies and processes in the United States.

**Officers:** Kevin Kreisler (Chair & CFO); David Winsness (Pres. & CEO)

**Auditor:** Rosenberg Rich Baker Berman & Company

**Securities:** Common Stock-Symbol GSCT.OB; OTC BB;  
333,345,602 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0923**

**Hydrogen Engine Center, Inc.**

2502 East Poplar Street  
Algona, IA 50511  
(515) 295-3178

NAICS		334513
Description		Combustion Engines Mfg.
Employees		25
Revenue	(mil)	\$0.28
Income	(mil)	(\$5.75)
Assets	(mil)	\$7.05
Liability	(mil)	\$3.01
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** LWBJ, LLP raised substantial doubt about the ability of Hydrogen Engine Center, Inc. to continue as a going concern after auditing its financial statements. Since inception, the Company has incurred substantial operating losses and expects to incur additional operating losses over the next several months. As of December 31, 2006, the Company has an accumulated deficit of approximately \$7.1 million. The auditor believes that continuing operations is dependent upon obtaining significant further financing.

**Intellectual Property:** The Company currently has 3 patents pending related to engine alignment and has approximately 64 potential patents in the development stage. These patents cover the use of hydrogen and other alternative fuels in any internal combustion engine. The future patent applications will apply to any internal combustion engine regardless of manufacturer or application. The Company also relies on trade secrets, common law trademark rights and trademark registrations. The Company intends to protect intellectual property via non-disclosure agreements, license agreements and limited information distribution. The Company's trademarks include HEC, OXX POWER, MINI OXX, 4 +1, OXX WORKS, OXX CART, OXX BOXX, BABY OXX, THE OTHER HYDROGEN, ENERGY IN A BOTTLE and OXX. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the design, manufacture, and distribution of spark-ignited internal combustion engines and power generator sets used in the industrial and power generation markets primarily in the United States and Canada.

**Officers:** Theodore G. Hollinger (Pres. & CEO); Theodore G. Hollinger (Dir.); Thomas A. Trimble (Dir.); Edward T. Berg (Dir.)

**Auditor:** LWBJ, LLP

**Securities:** Common Stock-Symbol HYEG.OB; OTC BB; 50,000,000 common shares outstanding as of April 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0924**

**instaCare Corporation**

2660 Townsgate Road, Suite 300  
Westlake Village, CA 91361  
(805) 446-1973

NAICS	517200
Description	Wireless Communications
Employees	6
Revenue (mil)	\$19.22
Income (mil)	(\$2.75)
Assets (mil)	\$0.37
Liability (mil)	\$2.60
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Weaver & Martin, LLC notes that instaCare Corporation has accumulated net losses from operations totaling \$18,058,490 at December 31, 2006. Even though the Company has begun to generate significant revenues, as of December 31, 2006, its gross profit from revenues is not sufficient to meet the overall financial requirements of the Company. The auditor states that these factors raise substantial doubt about the Company's ability to continue as a going concern.

**Intellectual Property:** Through its merger with Medicius, Inc. in 2002, the Company gained assignment of proprietary systems covered by a portfolio of pending utility patent applications that make claim to methods and systems for managing medical patient-specific information and concurrently implementing fulfillment of this information by multiple health-services related providers for medically-related services for use over a computer network. The proprietary systems allow for patient information to be gathered from multiple authorized sources; and then this information is provided at the point-of-care, and coordinated and compared with prescription formulary compliance, medical services providers and their payors, and multiple-rules based treatment plans provided by various sources. The original patent application, Patent Application 09776544, Information Management and Communications System and Method, consisting of 48 separate claims was filed on February 2, 2001. In July 2002, the Company completed a derivative application that added 17 additional claims to the application. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides Wi-Fi personal digital assistant technology to the lodging and satellite media industries.

**Officers:** Robert Jagunich (Chair); Keith Berman (Sec., Treas. & Dir.)

**Auditor:** Weaver & Martin, LLC

**Securities:** Common Stock-Symbol ISCR.OB; OTC BB;  
11,031,600 common shares outstanding as of May 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0925**

**Lamperd Less Lethal, Inc.**

1200 Michener Road  
Sarnia, Ontario, Canada N7S 4B1  
(519) 344-4445

NAICS	332992
Description	Ammunition Mfg.
Employees	6
Revenue	CDN\$(mil) \$0.37
Income	CDN\$(mil) (\$0.84)
Assets	CDN\$(mil) \$0.49
Liability	CDN\$(mil) \$0.49
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Lamperd Less Lethal, Inc. reported a net loss of CDN\$282,127 for the quarter ended March 31, 2007, compared to a net loss of CDN\$263,319 during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of CDN\$2,678,913 and stockholder's deficit of CDN\$227,657 at March 31, 2007. The Company also has strained liquidity with CDN\$172,911 in total current assets and CDN\$678,895 in total current liabilities.

**Intellectual Property:** The Company protects intellectual property with a variety of trademarks and trade secrets. In Canada and the United States, Lamperd has applied for a patent of the underlying technology used in its WASP composite round, which patent is currently pending. The patent application was filed by the University of Western Ontario under United States Provisional Patent Application No. 60/507,491. The following names are trademarks of its subsidiary, 1476246 Ontario Limited: Lamperd Less Lethal, Defender I, Defender II, Enforcer Suit I, Enforcer Suit II and Pinetree Law Enforcement. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company is a developer and manufacturer of civil defence products that are designed as a less lethal alternative to conventional weapons.

**Officers:** Barry Lamperd (Pres., CEO & Dir.); Jeff Kinsella (CFO); Sharon Scott (COO); D'arcy David William Bell (Dir.); Dominic Dicarolo (Dir.); Alexander Purvis Glenn (Dir.); Ed Ferguson (Dir.); Terry Smith (Dir.)

**Auditor:** Gregory J. Barber, CPA, P.C.

**Securities:** Common Stock-Symbol LLLI.OB; OTC BB;  
38,415,500 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0926**

**Leisure Direct, Inc.**

1070 Commerce Drive  
Perrysburg, OH 43551  
(419) 873-1111

NAICS		339920
Description		Swimming Pools Mfg.
Employees		3
Revenue	(mil)	\$0.00
Income	(mil)	(\$1.06)
Assets	(mil)	\$0.11
Liability	(mil)	\$2.38
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Rosenberg Rich Baker Berman & Company expressed substantial doubt on Leisure Direct, Inc.'s ability to continue as a going concern after auditing its financial statements. The Company incurred a loss of \$1,063,354 and \$3,020,391 during the years ended December 31, 2006 and 2005, respectively. Also, the auditor notes that as of December 31, 2006, the Company had no cash and current liabilities exceeded current assets by \$2,381,107.

**Intellectual Property:** On April 14, 2000, the Company entered into a joint venture agreement with Springfield Terra-Firma Properties, LTD. Under the terms of the agreement, the Company grants a license to use the "Olympic" name and trademark and to use the term "Factory Outlet" in signage and advertising, so long as Springfield sells products manufactured by the Company at certain minimum quantities. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company manufactures and assembles components of above ground pools in the United States.

**Officers:** John R. Ayling (Chair & CEO); Paul M. Hoag (Pres.)

**Auditor:** Rosenberg Rich Baker Berman & Company

**Securities:** Common Stock-Symbol LDTI.OB; OTC BB;  
13,188,128 common shares outstanding as of May 15, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0927**

**Life USA, Inc.**

2300 Canyon Boulevard, Suite 4  
Boulder, CO 80302  
(303) 415-1900

NAICS	325411
Description	Vitamin Supplements Mfg.
Employees	1
Revenue (mil)	\$0.75
Income (mil)	(\$0.76)
Assets (mil)	\$0.09
Liability (mil)	\$0.99
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Jaspers + Hall PC states that there is substantial doubt about the ability of Life USA, Inc. to continue as a going concern. The Company has limited activities, limited capital, debt in the amount of \$994,153, all of which is current, \$11,999 in cash and minimal other liquid assets, and no capital commitments. The auditor believes that the effects of such conditions could potentially cause the Company's bankruptcy.

**Intellectual Property:** The Company has proprietary rights to Agilflex™, the proprietary blend of Neptune Krill Oil™ and Sierra Sil™, which it has developed. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides clinical protocols and nutraceutical products.

**Officers:** Wesley Whiting (Pres., CEO, Acting CFO & Dir.)

**Auditor:** Jaspers + Hall PC

**Securities:** Common Stock-Symbol LFUI.OB; OTC BB;  
10,060,534 common shares outstanding as of April 10, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0928**

**Lucy's Café, Inc.**

2685 Park Center Drive, Building A  
Simi Valley, CA 93065  
(805) 433-8000

NAICS	517000
Description	Telecommunications
Employees	35
Revenue (mil)	\$20.11
Income (mil)	(\$13.93)
Assets (mil)	\$15.57
Liability (mil)	\$20.64
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Lucy's Café, Inc. incurred net losses of \$2,727,590 in 2004, \$1,111,815 in 2005 and \$13,930,465 in 2006. As a result of its recurring losses, the Company has an accumulated deficit of \$5,070,237 and stockholder's deficit of \$5,070,236 as of December 31, 2006. The Company also has strained liquidity with \$11,969,740 in total current assets and \$20,541,899 in total current liabilities.

**Intellectual Property:** The Company owns one registered patent and two patent applications filed with the U.S. Patent and Trademark Office. The patent relates to a system for routing toll free telephone calls. One patent application relates to the technology which combines instant messenger services with voice services. The other application relates to a method for transporting voice calls utilizing a combination of Internet Protocol and Asynchronous Transfer Mode. The Company owns numerous trademarks and service marks for telecommunication services, phone cards, computer software, computer hardware, and telephone sets and has applied for registration of trademarks and service marks to establish and protect brand names as part of its intellectual property strategy. [SEC Filing 10-KSB 04-17-07]

**Description:** On December 29, 2006, the Company acquired InterMetro Communications, Inc. through a business combination. The Company has built a national, private, proprietary voice-over Internet Protocol, or VoIP, network infrastructure offering an alternative to traditional long distance network providers.

**Officers:** Charles Rice (Chair, Pres. & CEO); Jon deOng (Chief Technology Officer & Dir.); Vincent Arena (CFO & Dir.); Joshua Toubert (Dir.); Robert Grden (Dir.); Douglas Benson (Dir.)

**Auditor:** Mayer Hoffman McCann PC

**Securities:** 45,525,614 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0929**

**MetaMorphix, Inc.**

8000 Virginia Manor Road, Suite 140  
Beltsville, MD 20705  
(301) 617-9080

NAICS		325412
Description		Pharmaceutical Products Mfg.
Employees		36
Revenue	(mil)	\$3.36
Income	(mil)	(\$18.68)
Assets	(mil)	\$10.25
Liability	(mil)	\$65.22
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** MetaMorphix, Inc., posted a \$4,410,151 net loss on \$794,321 of total revenues for the quarter ended March 31, 2007, as compared with a \$4,429,704 net loss on \$846,017 of total revenues in the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$9,682,423 in total assets and \$68,789,245 in total liabilities, resulting in a \$59,106,822 stockholders' deficit. The Company also reported strained liquidity with \$575,366 in total current assets and \$30,202,617 in total current liabilities.

**Intellectual Property:** At December 31, 2006, the Company either owns or has licensed 45 issued U.S. patents, 52 issued foreign patents, and 119 patents pending. The majority of these issued domestic and foreign patents relate to its GDF technology. These patents have been exclusively licensed from The Johns Hopkins University for exclusive use in the non-human field. These patents form the basis for its ability to operate and commercialize the genomic technologies in the livestock and companion animal sectors. There are a large number of applications pending in both the U.S. and foreign patent authorities. The Company also relies on trade secret protection for confidential and proprietary information. The Company has 6 registered trademarks and 14 trademarks are currently being prosecuted. [SEC Filing 10-KSB 04-03-07]

**Description:** The Company develops a pipeline of innovative products addressing all major livestock sectors, as well as developing products that enhance the health of companion animals.

**Officers:** Peter A. Meyer (Co-Chair); Edwin C. Quattlebaum (Co-Chair, Pres. & CEO); Thomas P. Russo (EVP, Treas. & CFO); Dennis Fantin (EVP & COO); Clifton Baile (Dir.); John R. Block (Dir.); Victor M. Casini (Dir.); Peter Drake (Dir.); Howard L. Minigh (Dir.); Edward T. Shonsey (Dir.)

**Auditor:** Deloitte & Touche LLP

**Securities:** 21,081,891 common shares outstanding as of May 1, 2007.

**Notes:** There is no established public trading market for the Company's common stocks.

[Return to top](#)



**Prospector  
Profile  
07.0930**

**Nano-Jet Corporation**  
15321 Main Street, Suite 102  
Duvall, WA 98019  
(425) 788-9823

NAICS	541710
Description	Environmental R&D
Revenue (mil)	\$0.00
Income (mil)	(\$0.21)
Assets (mil)	\$0.37
Liability (mil)	\$0.46
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Thomas J. Harris raised doubts about the ability of Nano-Jet Corporation to continue as a going concern after auditing its financial statements. The Company had suffered losses from development stage activities to date. In addition, current liabilities exceed current assets, and it has no operating funds.

**Intellectual Property:** Nano-Jet has licensed a proprietary technology and currently holds patents for this technology worldwide. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company's product, if developed, is anticipated to allow owners and operators of both gasoline and diesel powered vehicles to potentially increase fuel efficiency while reducing fuel emissions into the environment.

**Officers:** Ken Martin (CEO & Dir.); Xiao Lin (Dir.); Harry Harts (Dir.)

**Auditor:** Thomas J. Harris

**Securities:** Common Stock-Symbol NNJT.OB; OTC BB;  
40,569,633 common shares outstanding as of March 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0931**

**New Century Financial Corporation**

18400 Von Karman Avenue  
Irvine, CA 92612  
(949) 440-7030

NAICS		522310
Description		Mortgage Brokers
Employees		7,200
Revenue	(mil)	\$1,759.57
Income	(mil)	\$416.54
Assets	(mil)	\$26,147.09
Liability	(mil)	\$24,037.39
(for the year ended 12/31/2005)		

**Category:** IP Asset Sale

**Event:** New Century Financial Corp. and its subsidiaries seek to auction and sell certain technology-related assets as they no longer conduct their loan business. The Technology Assets include custom proprietary software applications, databases containing historical broker performance and quality data, fully operational primary and recovery data centers, and an application support organization. The Technology Assets may include trademarks and internet domain names related to the technology and a non-residential real property lease for the premises that houses the databases and supporting hardware in Irvine, California.

**Intellectual Property:** The Company has created a proprietary automated credit grading and pricing methodology that gives them the ability to more effectively evaluate credit risk and more efficiently price its products. [SEC Filing 10-K 03-16-07]

**Description:** The Company provides mortgage products to borrowers in the U.S. New Century Financial Corp. and its debtor-affiliates filed for Chapter 11 protection on April 2, 2007, with the U.S. Bankruptcy Court for the District of Delaware, lead case number 07-10417, before Judge Kevin J. Carey.

**Officers:** Brad A. Morrice (Pres. & CEO); Tajvinder S. Bindra (EVP & CFO); Kevin M. Cloyd (EVP); Patti M. Dodge (EVP); Joseph F. Eckroth, Jr. (EVP); Anthony T. Meola (EVP); Stergios Theologides (EVP & Gen. Counsel)

**Auditor:** KPMG LLP

**Attorneys:** Suzanne Uhland, Esq. and Austin K. Barron, Esq. of O'Melveny & Myers LLP; San Francisco, CA; (415) 984-8941

Mark D. Collins, Esq. and Michael J. Merchant, Esq. of Richards, Layton & Finger PA; Wilmington, DE; (302) 651-7531

**Securities:** Common Stock Symbol NEWC.PK; Other OTC; 55,470,607 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0932**

**NS8 Corporation**

11400 W Olympic Boulevard, Suite 200  
Los Angeles, CA 90064  
(310) 914-0175

NAICS	541511
Description	Custom Software Services
Employees	25
Revenue (mil)	\$0.22
Income (mil)	(\$10.14)
Assets (mil)	\$0.69
Liability (mil)	\$19.23
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** KMJ Corbin & Company LLP raised substantial doubt about the ability of NS8 Corporation to continue as a going concern after auditing its financial statements. During the years ended December 31, 2006 and 2005, the Company incurred net losses of \$10,135,508 and \$6,587,391, respectively, and had negative cash flows from operations of \$2,281,345 and \$4,176,075, respectively. In addition, the Company has an accumulated deficit of \$28,291,026 and stockholder's deficit of \$18,534,574 at December 31, 2006.

**Intellectual Property:** NS8 Corporation has three U.S. patent pending applications and two PCT applications. The applications claim priority to U.S. Provisional Patent Application No. 60/444,672, filed by CanOnline on February 4, 2003, titled "Method and Apparatus for Facilitating Third Party Representation Of An Object." Other applications claim priority to U.S. Provisional Patent Application filed with the U.S. Patent and Trademark Office, on July 16, 2004 for "Method and System for Managing the Authorized Use of Digital Works." The Company has also filed several trademarks in the United States and international territories in an attempt to protect intellectual property, including CANONLINE, NS8, SECURITY PROTOCOL INTEGRATION, SECURE DIGITAL CONTENT DISTRIBUTION. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the development and marketing of software-based technology products and related services for the delivery of on-demand media content over the Internet.

**Officers:** Anthony Alda (Chair, Pres., CEO & Chief Technology Architect); Leslie J. Ames (SVP, Sec. & Dir.); Carl Segal (EVP); Brent R. Bysouth (Chief Software Architect & Dir.); Ricardo Rosado (VP, CFO & Dir.); Melanie Thomson (COO); Michael W. Waage (Dir.); William Kunzweiler (Dir.)

**Auditor:** KMJ Corbin & Company LLP

**Securities:** Common Stock-Symbol NSEO.OB; OTC BB;  
119,248,701 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0933**

**Optigenex, Inc.**

750 Lexington Avenue  
New York, NY 10022  
(212) 905-0189

NAICS	541710
Description	Biotechnology
Employees	2
Revenue (mil)	\$0.30
Income (mil)	(\$7.36)
Assets (mil)	\$2.82
Liability (mil)	\$7.67
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Goldstein Golub Kessler LLP states that there is substantial doubt as to the ability of Optigenex, Inc. to continue as a going concern after auditing its financial statements. The auditor based this opinion on the Company's recurring losses from operations, a stockholders' deficit of approximately \$4,850,000 as of December 31, 2006, current rate of cash consumption and the uncertainty of liquidity-related initiatives.

**Intellectual Property:** The Company's core intellectual property lies in four U.S. patents issued for the extraction, testing and manufacturing processes of AC-11. It also owns seven registered trademarks for Time Machine, Age Manager, AC-11, Age Manager Professional, Optigene-X, Optigene and CMed-100. In addition, the Company has a trademark application pending for the name Activar. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the development and sale of nutritional supplement and skin care products for age-related issues in the United States.

**Officers:** William Walters(Chair); Daniel Zwiren (Pres., CEO & CFO); Michael Mullarkey (Dir.)

**Auditor:** Goldstein Golub Kessler LLP

**Securities:** Common Stock-Symbol OPGX.OB; OTC BB;  
11,158,736 common shares outstanding as of March 30, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0934**

**Protocall Technologies, Inc.**

47 Mall Drive  
Commack, NY 11725  
(631) 543-3655

NAICS	516110
Description	Internet Entertainment Sites
Employees	14
Revenue (mil)	\$1.07
Income (mil)	(\$5.99)
Assets (mil)	\$0.88
Liability (mil)	\$8.22
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Protocall Technologies, Inc. reported a net loss of \$2,709,813 for the quarter ended March 31, 2007, compared to a net loss of \$1,052,012 reported for the same quarter a year earlier. As a result of its recurring losses, the Company has an accumulated deficit of \$46,815,390 and stockholder's deficit of \$10,327,753 at March 31, 2007. The Company also has strained liquidity with \$175,083 in total current assets available to pay \$10,988,546 in total current liabilities.

**Intellectual Property:** The Company has received two United States patents for various aspects of its system. One patent protects the system by covering the retrieval of encrypted product from secure storage. The second patent further expands its intellectual property protection over its system and its use in the retail environment. The Company's intellectual property also includes the copyrighted source code for its Product Preview Station, Order Fulfillment Station, back-end rights management system, B2B software delivery system and Internet web delivery engine. The Company is the exclusive licensee for the use of the registered trademark SoftwareToGo®. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the development and commercialization of a system that enables retailers to produce packaged software, movie, and television digital media products, on demand, at their stores and at their Website fulfillment centers.

**Officers:** Peter Greenfield (Chair); Syd Dufton (Pres.); Bruce Newman (CEO & Dir.); Brenda Newman (SVP)

**Auditor:** Eisner LLP

**Securities:** Common Stock-Symbol PCLI.OB; OTC BB;  
81,546,332 common shares outstanding as of March 20, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0935**

**Rockelle Corporation**

162 Miller Place Road  
Miller Place, NY 11764  
(631) 244-9841

NAICS	722211
Description	Restaurants
Revenue (mil)	\$0.17
Income (mil)	(\$1.55)
Assets (mil)	\$2.09
Liability (mil)	\$1.24
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Infante & Company states that several factors create uncertainty about the ability of Rockelle Corp. to continue as a going concern. The auditor points out that the Company has an accumulated deficit of \$2,290,000; current liabilities exceeded current assets by more than \$953,000 at December 31, 2006; and it has incurred year-to-date losses of \$1,548,000 at December 31, 2006.

**Intellectual Property:** On March 16, 2006, the Company entered into a Multiple Unit Development Agreement with Frosted Mug Holdings, LLC which granted certain development rights to establish, operate and/or franchise Stewart's "Snack Bars" using the Frosted Mug Holdings proprietary restaurant service marks which currently include "Stewart's", Stewart's Root Beer" and "Original Drive In". It also signed an agreement, dated March 2005, with Kahala Corporation, for exclusive rights to Taco Time, in the greater New York City/Western Long Island metropolitan area. On Aug. 17, 2006, Rockelle announced that they have received approval from Massimo Zanetti Beverage, USA, the parent company of Chock Full o'Nuts, that permits Rockelle to combine other food concepts with a Chock Full o'Nuts Coffee Shop. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company operates as owner, operator, and franchiser of various types of quick service food establishments in Wal-Mart's locations in the United States.

**Officers:** Gerard A. Stephan (Chair, Pres. & CEO); Warren Rothouse (Dir.); Michael Stephan (Dir.); Gerard Stephan, Jr. (Dir.)

**Auditor:** Infante & Company

**Securities:** Common Stock-Symbol RKLC.OB; OTC BB;  
36,070,673 common shares outstanding as of April 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0936**

**Ronco Corporation**

61 Moreland Rd.  
Simi Valley, CA 93065  
(805) 433-1030

NAICS		332210
Description		Handtools Mfg.
Employees		117
Revenue	(mil)	\$58.72
Income	(mil)	(\$44.42)
Assets	(mil)	\$28.24
Liability	(mil)	\$24.37
(for the year ended 6/30/2006)		

**Category:** Bankruptcy

**Event:** Ronco Corporation and its affiliate, Ronco Marketing Corporation, filed for Chapter 11 protection on June 14, 2007 with the U.S. Bankruptcy Court for the Central District Of California, lead case number 07-12000, before Judge Geraldine Mund.

**Intellectual Property:** The Company acquired a significant amount of proprietary technology covering the design and manufacturer of its products. The Company relies on patents and confidentiality, non-disclosure and assignment of inventions agreements to protect proprietary rights. The Company holds over 30 patents on the proprietary design and manufacturing processes of its products. It also has trademarks in the U.S. and various countries around the world covering a variety of its marks. [SEC Filing 10-K 10-13-06]

**Description:** The Company, through its wholly owned subsidiary, Ronco Marketing Corp., engages in the development, marketing and distribution of consumer products for use in kitchen and home.

**Officers:** Paul Kabashima (Interim Pres., Interim CEO & COO); Ronald C. Stone (CFO); Harold D. Kahn (Dir.); Thomas J. Lykos, Jr. (Dir.); John S. Reiland (Dir.); Richard F. Allen, Sr. (Dir.)

**Auditor:** Mahoney & Company CPA PC

**Attorneys:** Stacia A. Neeley, Esq. of Klee, Tuchin, Bogdanoff and Stern LLP; Los Angeles, CA; (310) 407-4000

**Securities:** Common Stock-Symbol RNCP.PK; Other OTC;  
2,591,605 common shares outstanding as of September 30, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0937**

**Seawright Holdings, Inc.**

600 Cameron Street  
Alexandria, VA 22314  
(703) 340-1629

NAICS	312112
Description	Bottled Water Mfg.
Employees	1
Revenue (mil)	\$0.00
Income (mil)	(\$1.79)
Assets (mil)	\$2.78
Liability (mil)	\$3.51
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Seawright Holdings, Inc. reported a net loss of \$660,592 for the first quarter ending March 31, 2007, which is more than double the net loss reported during the first quarter of 2006 of \$306,795. As a result of its recurring losses, the Company has an accumulated deficit of \$4,460,162 and stockholder's deficit of \$1,117,969 as of March 31, 2007. It also has strained liquidity with only \$367,054 in total current assets available to pay \$2,072,738 in total current liabilities.

**Intellectual Property:** In June 2005, the Company purchased intellectual property from Quibell Partners LLC relating to the creation and bottling of flavored and non-flavored bottled water, including certain trademarks, service marks, trade names, service names and logos; various glass bottle designs; bottle label designs and artwork for water bottle carrypacks; formulas for flavored sparkling water and for teas; and web site coding. The Company also owns the domain name www.seawrightsprings.com. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in spring water bottling and distribution business in the United States.

**Officers:** Joel Sens (Pres., CEO, Treas. & Dir.); Jeffrey Sens (Dir.)

**Auditor:** Russell Bedford Stefanou Mirchandani LLP

**Securities:** Common Stock-Symbol SWRI.OB; OTC BB;  
9,760,166 common shares outstanding as of March 30, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0938**

**SenoRx, Inc.**

11 Columbia, Suite A  
Aliso Viejo, CA 92656  
(949) 362-4800

NAICS		423450
Description		Medical Equipment Retailer
Employees		122
Revenue	(mil)	\$25.51
Income	(mil)	(\$15.42)
Assets	(mil)	\$19.98
Liability	(mil)	\$24.09
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** SenoRx, Inc., posted a \$2,109,484 net loss on \$7,700,076 of total revenues for the quarter ended March 31, 2007, as compared with a \$2,342,968 net loss on \$5,834,148 of total revenues in the same quarter last year. At March 31, 2007, the Company's balance sheet showed \$16,478,054 in total assets, \$20,040,295 in total liabilities and \$11,800,000 in commitments and contingencies, resulting in a \$15,362,241 stockholders' deficit.

**Intellectual Property:** The Company has a strong portfolio of intellectual property. The Company currently has 43 issued United States patents primarily covering devices relating to breast biopsy, including biopsy site marking devices, excision devices, and balloon products, and a total of 13 granted national patents from eight different European countries. In addition, it has 66 pending United States patent applications and 19 pending European patent applications.  
[Company Website]

**Description:** The Company manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer.

**Officers:** Lloyd H. Malchow (Pres. & CEO); Kevin J. Cousins (VP-Finance & CFO); William F. Gearhart (VP-Sales & Mktg.); Eben S. Gordon (VP-Regulatory Affairs & Quality Assurance); Paul Lubock (Chief Tech. Officer)

**Auditor:** Deloitte & Touche LLP

**Securities:** Common Stock Symbol SENO; NasdaqGM;  
17,085,923 common shares outstanding as of April 30, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0939**

**SurgiLight, Inc.**

2100 Alafaya Trail, Suite 600  
Orlando, FL 32826  
(407) 482-4555

NAICS		334510
Description		Medical Laser Equipment Mfg.
Employees		4
Revenue	(mil)	\$0.03
Income	(mil)	(\$1.39)
Assets	(mil)	\$4.89
Liability	(mil)	\$5.37
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Richard L. Brown & Company P.A. expressed substantial doubt about SurgiLight Inc.'s ability to continue as a going concern after auditing its consolidated financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's losses from operations and net capital deficiency.

**Intellectual Property:** In October 2000, the Company acquired the inventory, intellectual properties and the technology of the ophthalmic laser division of Premier Laser Systems for \$3,745,000. As part of the acquisition, the Company acquired 14 patents and an additional 13 pending patents covering the infrared technology, certain applications in cataracts, glaucoma and other refractive surgeries. The Company has 4 issued U.S. patents and 5 pending U.S. patent applications relating to presbyopia treatment. The Company also owns 5 granted patents and 6 pending patent applications in foreign jurisdictions. [SEC Filing 10-KSB 06-07-07]

**Description:** The Company sells ophthalmic lasers and related products and services primarily used in refractive and presbyopia procedures in the United States and internationally.

**Officers:** Colette Cozean, Ph.D. (Chair & CEO); Louis P. Valente, CPA (Vice Chair); Timothy J. Shea (Pres., SEC & COO); Stuart E. Michelson, Ph.D. (Treas., CFO & Dir.); Ming-yi Hwang, Ph.D. (Dir.-R&D); Robert J. Freiberg, Ph.D. (Dir.); Ronald Higgins (Dir.); Richard Ajai (Dir.); Craig Collins (Dir.)

**Auditor:** Richard L. Brown & Company, P.A.

**Securities:** Common Stock-Symbol SRGL.OB; OTC BB;  
60,000,000 common shares outstanding as of May 28, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0940**

<b>Tweeter Home Entertainment Group, Inc.</b> 40 Pequot Way Canton, MA 02021 (781) 830-3000	NAICS Description Employees Revenue (mil) Income (mil) Assets (mil) Liability (mil) (for the year ended 9/30/2006)	443112 Electronics Stores 3,200 \$775.29 (\$16.48) \$258.57 \$190.42
--	---	---

**Category:** Bankruptcy

**Event:** Tweeter Home Entertainment Group, Inc., and its debtor-affiliates filed for Chapter 11 protection on June 11, 2007, with the U.S. Bankruptcy Court for the District of Delaware, lead case number 07-10787, before Judge Peter J. Walsh.

**Intellectual Property:** The Company has registered the "Tweeter" and "Tweeter etc." service marks with the United States Patent and Trademark Office. It has also registered the "Prosolutions" trademark and the "AVi.d. Member," "Slamfest," "Wise Buys" and "Picture Perfect" service marks with the United States Patent and Trademark Office. However, the Company has not registered "hifi buys," "Sound Advice" and some of its other service marks. [SEC Filing 10-K 12-21-06]

**Description:** The Company sells audio, video, entertainment, and mobile consumer electronic products through its chain of stores under the Tweeter, hifi buys, Sound Advice, and Showcase Home Entertainment names.

**Officers:** Samuel Bloomberg (Chair); Joseph McGuire (Pres., CEO, & Dir.); Gregory Hunt (SVP & CFO); Robert Staples (SVP-Sales & Installation Services); Jeffrey Bloomberg (Dir.); Michael Cronin (Dir.); John Esposito (Dir.); Steven Fischman (Dir.); Karen Kaplan (Dir.); John Mahoney (Dir.); Jeffrey Stone (Dir.)

**Auditor:** Deloitte & Touche LLP

**Attorneys:** Skadden, Arps, Slate, Meagher & Flom LLP; Wilmington, Del.; (302) 651-3000  
Gregg M. Galardi, Esq.  
Mark L. Desgrosseilliers, Esq.

**Securities:** Common Stock Symbol TWTR; NasdaqGM;  
25,527,943 common shares outstanding as of February 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0941**

**Valence Technology, Inc.**

12201 Technology Boulevard, Suite 150  
Austin, TX 78727  
(512) 527-2900

NAICS	335912
Description	Batteries Mfg.
Employees	36
Revenue (mil)	\$16.67
Income (mil)	(\$22.25)
Assets (mil)	\$19.20
Liability (mil)	\$78.51
(for the year ended 3/31/2007)	

**Category:** Audit Concerns

**Event:** PMB Helin Donovan LLP expressed substantial doubt about Valence Technology, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the year ended March 31, 2007. The auditing firm pointed to the Company's recurring losses from operations, negative cash flows from operations and net stockholders' capital deficit. The Company posted a \$22,251,000 net loss on \$16,674,000 of total revenues for the year ended March 31, 2007, as compared with a \$32,924,000 net loss on \$17,214,000 of total revenues in the prior year. At March 31, 2007, the Company's balance sheet showed \$19,200,000 in total assets and \$78,508,000 in total liabilities, resulting to a \$67,918,000 stockholders' deficit.

**Intellectual Property:** The Company relies on patent protection for certain designs and products. It holds approximately 140 United States patents, which have expiration dates through 2025 and has about 38 patent applications pending in the United States. It continually prepares new patent applications for filing in the United States. The Company also actively pursues patent protection in certain foreign countries. In addition to potential patent protection, the Company relies on the laws of unfair competition and trade secrets to protect proprietary rights. It attempts to protect trade secrets and other proprietary information through agreements with customers and suppliers, proprietary information agreements with employees and consultants and other security measures. [SEC Filing 10-K 06-14-07]

**Description:** The Company develops and commercializes phosphate-based lithium-ion technology, known as Saphion.

**Officers:** Carl E. Berg (Chair); Robert L. Kanode (Pres., CEO & Dir.); Richard Hanna (VP); Joel Sandahl (VP); Thomas F. Mezger (CFO & Asst. Sec.); Roger A. Williams (Gen. Counsel & Asst. Sec.); Vassilis G. Keramidas (Dir.); Bert C. Roberts (Dir.)

**Auditor:** PMB Helin Donovan LLP

**Securities:** Common Stock Symbol VLNC; NasdaqSC;  
108,160,489 common shares outstanding as of June 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0942**

**Vaso Active Pharmaceuticals, Inc.**

99 Rosewood Drive, Suite 260  
Danvers, MA 01923  
(978) 750-1991

NAICS	325412
Description	Pharmaceuticals Mfg.
Employees	4
Revenue (mil)	\$0.10
Income (mil)	(\$2.84)
Assets (mil)	\$0.40
Liability (mil)	\$5.09
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Stowe & Degen states that Vaso Active Pharmaceuticals, Inc.'s stockholders' deficiency and deficiency in working capital at December 31, 2006, raise substantial doubt about the Company's ability to continue as a going concern.

**Intellectual Property:** BioChemics, Inc. granted the Company an exclusive, irrevocable, worldwide license to use and practice the VALE patents and PENTtoCORE technology in order to commercialize, market and sell OTC pharmaceutical products. In addition, BioChemics has 4 other patents pending domestically. Internationally, BioChemics has been issued foreign patents in 17 countries and patents pending in 7 others. BioChemics also owns 16 registered trademarks, including Osteon, RepiDerm and PENTtoCORE. The Company owns the U.S. trademark protection for the names "Termin8" and "A-R Extreme." [SEC Filing 10-KSB 04-17-07]

**Description:** The Company engages in the commercialization, marketing, and sale of over the counter pharmaceutical products that incorporate the vaso active lipid encapsulated technology or a proprietary PENTtoCORE technology.

**Officers:** Robert E. Anderson (Chair); Joseph Frattaroli (Acting CEO); Stephen Carter, Ph.D. (VP, Chief Scientific Officer & Dir.); Ronald Guerriero (Dir.); D'Anne Hurd (Dir.); Bruce A. Shear (Dir.); Brian J. Strasnick, Ph.D. (Dir.)

**Auditor:** Stowe & Degen

**Securities:** Common Stock-Symbol VAPH.OB; OTC BB;  
10,328,604 common shares outstanding as of April 10, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0943**

**Vistula Communications, Inc.**

Suite 801, 405 Park Avenue  
New York, NY 10022  
(212) 317-8900

NAICS	541511
Description	Custom Software Services
Employees	19
Revenue (mil)	\$1.09
Income (mil)	(\$19.53)
Assets (mil)	\$27.20
Liability (mil)	\$11.29
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Vistula Communications, Inc. has incurred a net loss of \$19,530,105 for the year ended December 31, 2006 and had an accumulated deficit of \$36,107,104 at December 31, 2006. Further, the Company had cash of \$195,223 and a working capital deficit at December 31, 2006 of \$4,792,654. PKF states that these factors, among others, may indicate that the Company will be unable to continue as a going concern.

**Intellectual Property:** The Company relies on trademark and copyright law, trade secret protection, and confidentiality, license and other agreements with employees, customers, partners and others to protect intellectual property rights and the intellectual property rights of licensors. The Company has filed for registration with the U.S. Patent and Trademark Office for the trademark V-Cube™. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides state-of-the-art software and high-margin services to telecommunications carriers, service providers, network operators, and large scale distributors.

**Officers:** Rupert Galliers-Pratt (Chair, Pres. & CEO); Jared P. Taylor (CFO, Sec. & Treas.); Ian Cope (COO); J. Marcus Payne (Dir.); Anthony Warrender (Dir.); Jack Early (Dir.)

**Auditor:** PKF

**Securities:** Common Stock-Symbol VSTLE.OB; OTC BB; 66,964,898 common shares outstanding as of April 6, 2007.

[Return to top](#)